Lifecare ASA Annual Report 2025

24 Mar 2026 07:01 CET

Lifecare ASA has today released its 2025 Annual Report, providing insights
into Lifecare's business strategy, key milestones, and next steps toward
obtaining CE certification for its glucose sensor for use in the human market.

2025 has been a year of tranisition and execution. We have moved from
technology validation to a fully integrated and controlled system - enabling
us to produce the same implant with the same functionality, every time. This
positions us to further optimise manufacturing processes and meet regulatory
expectations as we progress toward clinical studies and commercialisation.
This has been a decisive transition for Lifecare.

While 2024 demonstrated our sensor technology in an implantable format, 2025
was about converting that breakthrough into a robust, repeatable and scalable
system. During the year, we moved from validating feasibility to demonstrating
controlled, system-level execution of a fully integrated implantable
Continuous Glucose Monitoring platform. This milestone significantly reduces
the platform's technical risk profile. Lifecare now moves forward with clear
priorities: progressing regulatory approvals for first-in-human trials
followed by the regulatory CE trial.

The Annual Report is published in both the European Single Electronic Format
(ESEF) and as a PDF.

Additionally, Lifecare has published its 2025 Remuneration Report in
accordance with the Norwegian Public Limited Liability Companies Act, section
6-16b (2).

The reports are available on Lifecare's
website: https://lifecare.no/investor/reports-presentations/.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-03-24 07:00 CET.

More information:
Access the news on Oslo Bors NewsWeb site

669136_Lifecare Annual Report 2025.pdf
669136_lifecare-2025-12-31-1-en.zip